Summary
BiomimX Beating organs-on-chips (OoC) are in vitro miniaturized and living replica of human organs and diseases,
building upon cutting-edge technologies and human cells. Beating OoC provide a faithful replication of native human
physiology integrating miniaturized 3D cell culture techniques, mechanical stimulation (uBeat®) and electrical recording
capabilities (uSense). BiomimX’s proprietary key technology (uBeat®) supports 3D human cell cultures and integrates a
controlled and tunable mechanical stimulation system. uBeat® leads to the generation of mature and functional miniaturized
replication of human organs adequate to test compounds toxicity/functionality in a high-throughput fashion. Integration of
uSense allows real-time evaluation of clinically relevant parameters from the established beating models. BiomimX’s
Beating OoC represent a safer, more efficient and faster alternative to poorly predictable preclinical models to date available in
the drug discovery pipeline (DDP). BiomimX already demonstrated the validity of its Beating OoC models in two critical fields of
the drug discovery pipeline: uHeart (human beating heart-on-chip) has been applied as early predictor of drug functional
cardiotoxicity, uKnee (first in vitro model of human OA) has shown its predictive potential for the discovery of new targets for
an unmet pathology.
Also thanks to the contribution of Women TechEU programme, BiomimX aims at demonstrating the unprecedented potential of its disruptive innovation in reshaping the market of drug development, by i) boosting technological aspects (i.e. through an intensive industrialization process of BiomimX patented technologies) and ii) proving the versatility of its innovation and its capacity to adapt to a manifold of indications and market spaces. In line with the 3R principle, BiomimX final vision is to reduce and eventually replace animal experimentations within the next 15 years.
building upon cutting-edge technologies and human cells. Beating OoC provide a faithful replication of native human
physiology integrating miniaturized 3D cell culture techniques, mechanical stimulation (uBeat®) and electrical recording
capabilities (uSense). BiomimX’s proprietary key technology (uBeat®) supports 3D human cell cultures and integrates a
controlled and tunable mechanical stimulation system. uBeat® leads to the generation of mature and functional miniaturized
replication of human organs adequate to test compounds toxicity/functionality in a high-throughput fashion. Integration of
uSense allows real-time evaluation of clinically relevant parameters from the established beating models. BiomimX’s
Beating OoC represent a safer, more efficient and faster alternative to poorly predictable preclinical models to date available in
the drug discovery pipeline (DDP). BiomimX already demonstrated the validity of its Beating OoC models in two critical fields of
the drug discovery pipeline: uHeart (human beating heart-on-chip) has been applied as early predictor of drug functional
cardiotoxicity, uKnee (first in vitro model of human OA) has shown its predictive potential for the discovery of new targets for
an unmet pathology.
Also thanks to the contribution of Women TechEU programme, BiomimX aims at demonstrating the unprecedented potential of its disruptive innovation in reshaping the market of drug development, by i) boosting technological aspects (i.e. through an intensive industrialization process of BiomimX patented technologies) and ii) proving the versatility of its innovation and its capacity to adapt to a manifold of indications and market spaces. In line with the 3R principle, BiomimX final vision is to reduce and eventually replace animal experimentations within the next 15 years.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101071659 |
| Start date: | 01-06-2022 |
| End date: | 30-11-2022 |
| Total budget - Public funding: | - 75 000,00 Euro |
Cordis data
Original description
BiomimX Beating organs-on-chips (OoC) are in vitro miniaturized and living replica of human organs and diseases,building upon cutting-edge technologies and human cells. Beating OoC provide a faithful replication of native human
physiology integrating miniaturized 3D cell culture techniques, mechanical stimulation (uBeat®) and electrical recording
capabilities (uSense). BiomimX’s proprietary key technology (uBeat®) supports 3D human cell cultures and integrates a
controlled and tunable mechanical stimulation system. uBeat® leads to the generation of mature and functional miniaturized
replication of human organs adequate to test compounds toxicity/functionality in a high-throughput fashion. Integration of
uSense allows real-time evaluation of clinically relevant parameters from the established beating models. BiomimX’s
Beating OoC represent a safer, more efficient and faster alternative to poorly predictable preclinical models to date available in
the drug discovery pipeline (DDP). BiomimX already demonstrated the validity of its Beating OoC models in two critical fields of
the drug discovery pipeline: uHeart (human beating heart-on-chip) has been applied as early predictor of drug functional
cardiotoxicity, uKnee (first in vitro model of human OA) has shown its predictive potential for the discovery of new targets for
an unmet pathology.
Also thanks to the contribution of Women TechEU programme, BiomimX aims at demonstrating the unprecedented potential of its disruptive innovation in reshaping the market of drug development, by i) boosting technological aspects (i.e. through an intensive industrialization process of BiomimX patented technologies) and ii) proving the versatility of its innovation and its capacity to adapt to a manifold of indications and market spaces. In line with the 3R principle, BiomimX final vision is to reduce and eventually replace animal experimentations within the next 15 years.
Status
SIGNEDCall topic
HORIZON-EIE-2021-SCALEUP-01-03Update Date
09-02-2023
Images
No images available.
Geographical location(s)
